We have been hearing rumblings over the past few months about a war going on between Osteotech and Apatech. In head to head competition, Osteotech totals revenues of around $100 million while Apatech, although privately held, is rumored to have revenues north of $50 million.
Osteotech is going through a constant change and it was reported that they recently “reorganized” their recently “reorganized” management team. They have always been known as a company with good products but a somewhat lack of focus and direction. It has also been rumored that they have put Actifuse, and its clinical data, squarely in their sites.
The question that remains is which company is more likely to turn the corner? The $100 million dollar mark generally creates a turning point for an organization where they can either flourish or essentially sit idle.
What have you heard on the street? Is Stryker likely to buy either company since it basically has no biologics presence anymore? Which product has more promise?
Share your thoughts on our commenting system. It asks for your email only to send you notification of additions to the thread. If you don’t want to supply it, feel free to use one from make believe land.
With so many biologics companies peddling “new & improved” products, how is anyone supposed to really know who's is the best for their patients?
Apatech has a lot of good things going for them. They've grown like crazy and have a talented team in the field. This is far from over. Isto looks like they have a great product as well. Stem Cells seem to be the future of this market. Differentiation is the key. There seems to be a lot of growth opportunity still, especially since Infuse is priced so high.